KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Operating Expenses: 2018-2025

Historic Operating Expenses for Adaptive Biotechnologies (ADPT) over the last 8 years, with Sep 2025 value amounting to $83.7 million.

  • Adaptive Biotechnologies' Operating Expenses rose 5.84% to $83.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.9 million, marking a year-over-year decrease of 12.23%. This contributed to the annual value of $341.5 million for FY2024, which is 14.05% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Operating Expenses stood at $83.7 million, which was down 0.28% from $83.9 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Operating Expenses' 5-year high stood at $116.9 million during Q4 2023, with a 5-year trough of $79.1 million in Q3 2024.
  • For the 3-year period, Adaptive Biotechnologies' Operating Expenses averaged around $89.9 million, with its median value being $88.9 million (2023).
  • As far as peak fluctuations go, Adaptive Biotechnologies' Operating Expenses skyrocketed by 52.46% in 2021, and later plummeted by 30.43% in 2024.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' Operating Expenses stood at $99.5 million in 2021, then fell by 5.17% to $94.4 million in 2022, then increased by 23.80% to $116.9 million in 2023, then tumbled by 30.43% to $81.3 million in 2024, then climbed by 5.84% to $83.7 million in 2025.
  • Its last three reported values are $83.7 million in Q3 2025, $83.9 million for Q2 2025, and $82.0 million during Q1 2025.